Sun Pharma - ‘Specialty’ Way of Driving Growth Prospects
The overall R&D expenditure is expected to increase by 33% YoY in FY24 and maintain an 18% CAGR over FY24-26 to support clinical development of...
156 Views
Sun Pharmaceutical Industries: SUNP’s Subsidiary Taro Posts Strong Performance.
Taro posted strong sales growth of 13% YoY to USD 157 mn (+6% QoQ), led by new launches with a sharp improvement in adjusted EBITDA to USD 24 mn
194 Views
Pharma and Healthcare (Q1FY25E Results Preview): Start the Year on a Strong Nod
The India Pharma & Healthcare sector is expected to maintain the growth momentum in Q1FY25E. We expect our coverage universe to see 11%/13% YoY...
217 Views
Pharmaceuticals: US Generic Growth to Stay, Selective on Structural Play
The pharmaceutical sector, emerging from the volatility of the past two post-pandemic and geopolitically tumultuous years, is now on a recovery...
220 Views
Sun Pharma Industries - One-Time Costs Hit Earnings
Adjusting for exceptional items (Rs39,358mn), Sun Pharma’s 4QFY22 net earnings (Rs15,821mn) was slightly lower than expectations
182 Views